<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746911</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ-151-216</org_study_id>
    <nct_id>NCT04746911</nct_id>
  </id_info>
  <brief_title>Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)</brief_title>
  <official_title>An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 2 to 5 Years Old) With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcutis Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcutis Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in&#xD;
      pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite</measure>
    <time_frame>Week 4</time_frame>
    <description>Plasma levels of circulating roflumilast and its major N-oxide metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Week 4</time_frame>
    <description>Number of participants with adverse events during treatment will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of application site reactions</measure>
    <time_frame>Week 4</time_frame>
    <description>Number of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Psoriasis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 cream 0.3%</intervention_name>
    <description>ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks</description>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
    <other_name>Topical roflumilast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent of parent(s) or legal guardian.&#xD;
&#xD;
          -  Males or females, 2 to 5 years old (inclusive).&#xD;
&#xD;
          -  Clinical diagnosis of psoriasis vulgaris of at least 2 months duration as determined&#xD;
             by the Investigator or through subject interview. Stable disease for the past 3 weeks.&#xD;
&#xD;
          -  Psoriasis vulgaris on the face, extremities, trunk, and/or intertriginous areas&#xD;
             involving at least 2% of BSA (excluding the scalp, palms, and soles).&#xD;
&#xD;
          -  An Investigator Global Assessment of disease severity (IGA) of at least Mild ('2') at&#xD;
             Baseline.&#xD;
&#xD;
          -  Subject has adequate venous access for PK sampling in areas not involved by plaque&#xD;
             psoriasis and not being treated with ARQ-151 (e.g., back of the hands).&#xD;
&#xD;
          -  In good health as judged by the Investigator, based on medical history, physical&#xD;
             examination, 12-lead electrocardiogram (ECG), serum chemistry labs and hematology&#xD;
             values.&#xD;
&#xD;
          -  Subjects and parent(s)/legal guardian(s) are considered reliable and capable of&#xD;
             adhering to the Protocol and Visit Schedule, according to the judgment of the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any serious medical or psychiatric condition or clinically significant&#xD;
             laboratory, ECG, vital signs, or physical examination abnormality that would prevent&#xD;
             study participation or place the subject at significant risk, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Planned initiation or changes to concomitant medication that could, in the opinion of&#xD;
             the Investigator, affect psoriasis vulgaris&#xD;
&#xD;
          -  Current diagnosis of non-plaque form of psoriasis (e.g., guttate,&#xD;
             erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis).&#xD;
             Current diagnosis of drug-induced psoriasis.&#xD;
&#xD;
          -  Subjects with any condition on the treatment area which, in the opinion of the&#xD;
             Investigator, could confound efficacy measurements.&#xD;
&#xD;
          -  Subjects who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inducers for&#xD;
             2 weeks prior to Baseline/Day 1and during the study period.&#xD;
&#xD;
          -  Subjects who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inhibitors&#xD;
             for 2 weeks prior to Baseline/Day 1 and during the study period.&#xD;
&#xD;
          -  Subjects who are unwilling to refrain from prolonged sun exposure and from using a&#xD;
             tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to&#xD;
             Baseline/Day 1 and during the study.&#xD;
&#xD;
          -  Subjects who cannot discontinue specific systemic therapies and/or topical therapies&#xD;
             prior to the Baseline/Day 1 and during the study period according to the protocol.&#xD;
&#xD;
          -  Subjects with any infection requiring oral or intravenous administration of&#xD;
             antibiotics, antifungal or antiviral agents within 2 weeks prior to Baseline/Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Berk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arcutis Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arcutis Study Inquiry</last_name>
    <phone>805 418 5006</phone>
    <phone_ext>5</phone_ext>
    <email>studyinquiry@arcutis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arcutis Clinical Site 603</name>
      <address>
        <city>Mountain Brook</city>
        <state>Alabama</state>
        <zip>35223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 604</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 609</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 608</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 611</name>
      <address>
        <city>Rancho Santa Margarita</city>
        <state>California</state>
        <zip>92688</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 610</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 602</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 613</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 601</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 607</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 606</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Study Site 619</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 605</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 630</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

